莱茵生物筹划重大事项 今日起停牌

Core Viewpoint - The company, Rhein Biotech, is planning a change in control and has announced a suspension of trading due to the potential transfer of shares and voting rights by its controlling shareholder, Qin Benjun [1][2]. Group 1: Control Change Announcement - On December 8, the company received a notification from its controlling shareholder, Qin Benjun, regarding the planned change in control [1]. - Qin Benjun intends to transfer part of his shares to Guangzhou Defu Nutrition and will voluntarily relinquish voting rights for some of his shares [2]. - A "Control Change Intent Agreement" has been signed, but specific transaction details are still under negotiation [1][2]. Group 2: Transaction Details - The company plans to issue shares to acquire an 80% stake in Beijing Jinkangpu from Defu Jinkangpu Holdings and Xiamen Defu Jinkangpu Investment Partnership [2]. - The transaction aims to integrate Beijing Jinkangpu into the listed company structure, enhancing business synergies [2]. Group 3: Financial Performance - For the first three quarters of the year, the company reported a revenue of 1.272 billion yuan, representing a year-on-year increase of 8.73% [3]. - The net profit attributable to shareholders was 70.3953 million yuan, showing a year-on-year decline of 30.73% [3].